EMA accepts marketing application for Imfinzi to treat NSCLC patients
The European Medicines Agency (EMA) has accepted a marketing authorisation application (MAA) for AstraZeneca and MedImmune ’s Imfinzi (durvalumab) to treat patients with locally advanced, unresectable non-small-cell lung cancer (NSCLC).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: AstraZeneca | Cancer | Cancer & Oncology | European Medicines Agency (EMA) | Lung Cancer | Marketing | Non-Small Cell Lung Cancer